Improving clinical trial design for hepatocellular carcinoma treatments

Despite its place as the third leading cause of cancer deaths worldwide, there are currently no approved chemotherapeutic agents, devices or techniques to treat hepatocellular carcinoma. Importantly, there have been no phase III studies demonstrating survival benefit, nor any randomized studies of t...

Full description

Bibliographic Details
Main Authors: Robert G. Gish, Garrett Hisatake
Format: Article
Language:English
Published: Frontiers Media S.A. 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/139